Eli Lilly has announced a 70% price cut for its most commonly used forms of insulin, with a list price of $25 a vial as of May 1, and out-of-pocket costs capped at $35 a month for those with commercial insurance. The move comes in response to criticism of insulin prices, which have led to rationing and other health risks for those with diabetes. Eli Lilly is also expanding its Insulin Value Program to help make insulin more accessible and affordable.